Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke
| Autor: | Kjeldsen, Sverre E, Lyle, Paulette A, Kizer, Jorge R, Oparil, Suzanne, Høieggen, Aud, Os, Ingrid |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
hypertension
Review stroke hydrochlorothiazide Losartan combination therapy Risk Factors cardiovascular system Humans Drug Therapy Combination angiotensin receptor blocker Angiotensin II Type 1 Receptor Blockers hormones hormone substitutes and hormone antagonists Antihypertensive Agents circulatory and respiratory physiology |
| Zdroj: | Vascular Health and Risk Management |
| ISSN: | 1178-2048 1176-6344 |
| Popis: | A fixed-dose combination of losartan/hydrochlorothiazide (HCTZ) therapy may be a logical choice for antihypertensive treatment, including for initial therapy in patients with blood pressure elevation >20/10 mmHg above treatment target. The renin–angiotensin– aldosterone–system-activating effect of hydrochlorothiazide augments the efficacy of blocking the angiotensin II type 1 (AT1) receptor with losartan. Some adverse effects associated with hydrochlorothiazide, including increased risk for new-onset diabetes mellitus, may be offset by losartan. Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group. The efficacy, tolerability, and convenience of losartan/HCTZ combination therapy may increase patient compliance and lower risk for stroke, a devastating outcome in patients with hypertension. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|